ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

43.20
-0.20
(-0.46%)
Closed 06 December 8:00AM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
43.20
Bid
41.00
Offer
42.00
Volume
542
43.20 Day's Range 43.80
21.40 52 Week Range 58.50
Previous Close
43.40
Open
43.80
Last Trade
47
@
43.2
Last Trade Time
Average Volume (3m)
114
Financial Volume
-
VWAP
-

2GH Latest News

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus...

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10043.247437546.60089286DE
4-6.8-13.65051.540.49946.46118598DE
12-2.2-4.8458149779745.451.540.411447.6509915DE
26-3.4-7.2961373390646.657.540.415348.80237835DE
5221.800001101.86916831221.39999958.521.39999917044.3573342DE
15619.481.51260504223.858.51916541.98058262DE
26019.481.51260504223.858.51916541.98058262DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
17DArcadia Biosciences Inc
5.15 €
(99.61%)
10.94k
1KPAProtara Therapeutics Inc
5.90 €
(75.60%)
16.79k
1ZY0Medaro Mining Corp
0.17 €
(63.46%)
54.1k
TE9Teco 2030 ASA
0.0398 €
(61.79%)
1.04M
L7C2Windfall Geotek Inc
0.006 €
(50.00%)
18k
NL8Genesis Ai Corp
0.0056 €
(-58.82%)
10k
0PV2Moovly Media Inc
0.0025 €
(-58.33%)
859
CNWCodon AG
0.0065 €
(-40.91%)
1.5k
BLEBluebird bio Inc
0.4205 €
(-40.13%)
233.06k
DW8Tantalex Lithium Resources Corp
0.0115 €
(-39.47%)
2k
D7GNel ASA
0.2679 €
(0.15%)
5.5M
AXIAtos SE
0.20 €
(-36.51%)
4.95M
PLUNPlug Power Inc
2.2955 €
(13.55%)
3.17M
R9BDeFi Technologies Inc
3.06 €
(-6.13%)
2.98M
TUI1Tui AG
8.318 €
(5.26%)
2.21M

Discussion

View Full Feed
Gamco Gamco 3 minutes ago
InterDigital Declares Regular Quarterly Cash Dividend
December 05 2024 - 4:05PM

InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that its Board of Directors has declared a regular quarterly cash dividend of $
IDCC
BrianHaugli BrianHaugli 3 minutes ago
See you all on the IR call in a few! I've pulled up all the questions I can find here and will answer during Q&A.

Thanks for the support and another year of growth!
SDCH
surfkast surfkast 3 minutes ago
LOL. If you believe Hans.
dig4gold dig4gold 3 minutes ago
Very disappointing day. We need something good to happen here and then continuous updates from management. They have such a perfect opportunity here with BTC as high as it is now.
CGAC
TRUISM TRUISM 3 minutes ago
Over a month of editing and retakes can make anything presentable.

That is why I said it was "almost perfection". 😀
KBLB
fung_derf fung_derf 4 minutes ago
Ð...Yesterday I picked up some $INOD under $45. Currently forming a flag formation, which I am expecting another big spike coming from it within the next few weeks.
I'd say a break below ......$33 and we can assume it's not working.
This market is crazy! Everyone wants AI stocks, no
INOD
getmoreshares getmoreshares 4 minutes ago
we need an update and tier upgrade! No reason we should be this low
CGAC
koolmc koolmc 4 minutes ago
lol around 90 bucks worth of stock you try way too hard
CNNA
Citrati Citrati 4 minutes ago
Update to Daily from 7 days ago. ( Not a classic double top)
Weekly shows it is 200period resistance.
Tomorrow likely confirms todays fall through supports and we look hopefully for support between closing price and the upward 50period currently 6.94.

https://investorsh
surfkast surfkast 5 minutes ago
Don't know about the meteor but they hijacked photos from another web site. E-Power Resources
https://e-powerresources.com
Photos from 2024 Tetepisca Exploration Program
koolmc koolmc 5 minutes ago
lol to bad you left the other stock early swimpy it went today, maybe leave this one too lmao
CGAC
Backstabbed Backstabbed 5 minutes ago
$BURU - hopefully soon! Been hearing it since October 2024!
BURU
KnicksStockChamp KnicksStockChamp 5 minutes ago
So the mods are just going to delete all posts offering comparisons or considerations for the sector that YCRM is trying to be in?
YCRM
price_and_volume price_and_volume 5 minutes ago
Due to be sentenced next month?
But… But… Spivak is ENGAGED!!! https://www.justice.gov/usao-ndoh/multiple-victim-case-update-us-v-paul-spivak-et-al
GSTC
trainer2 trainer2 5 minutes ago
Not bragging but i said .11 or .12 today. Tomorrow maybe .13
KBLB
Perk_Idaho Perk_Idaho 6 minutes ago
Hey Bear - I lost my mother in August to this. I hope something can be done to help her. Nothing could be done to help my my mother. My advice is to spend as much quality time as you can right now with your sister. Maybe take her on a family trip, somewhere she has always wanted to go. Not doing tha
NWBO
I-Glow I-Glow 6 minutes ago
The revenue is fabricated - the financials aren't vetted by the SEC and the OTCM doesn't have any enforcement abilities - the only thing they can do is put a Shell Risk on the company or place a CE on the company.

"I dont have the answers you are looking for, what I know is the revenu
OTCM
trade15 trade15 6 minutes ago
Janice

I'm pretty sure he was the Waaco Kid. I'm sure I still have print outs from his email service at one of my rural residences. I kept all that stuff from back then. Still have the original broker tickets from my first big mining stock win when I was still in school. But what we
Huggy Bear Huggy Bear 6 minutes ago
There is no volume man. No interest in this scam.
ANAS
Lucabazi Lucabazi 7 minutes ago
I agree with you that Ntephe is about to pull off several things that will add value to Erhe so I’ll see you in that line to congratulate him also!
ERHE
badog badog 7 minutes ago
Link detailing deal, please.

There won't be. This is referred to as continued speculation.

Badog
ERHE
TrackDude TrackDude 7 minutes ago
All your listed cons are all easily addressable with one shareholder call.  
NXPL
m$teamworkotc m$teamworkotc 7 minutes ago
Jim merges in a new company its going to go NUCLEAR from 0004 pal
GSTC

Your Recent History

Delayed Upgrade Clock